Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $10.8 million.

  • Iovance Biotherapeutics' Capital Expenditures rose 373.95% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.7 million, marking a year-over-year increase of 175.01%. This contributed to the annual value of $11.1 million for FY2024, which is 50.34% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Capital Expenditures stood at $10.8 million, which was up 45.34% from $7.5 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Capital Expenditures peaked at $10.8 million during Q3 2025, and registered a low of $442,000 during Q2 2024.
  • Its 3-year average for Capital Expenditures is $5.3 million, with a median of $4.2 million in 2024.
  • Per our database at Business Quant, Iovance Biotherapeutics' Capital Expenditures crashed by 94.03% in 2024 and then soared by 1,588.01% in 2025.
  • Iovance Biotherapeutics' Capital Expenditures (Quarterly) stood at $3.5 million in 2023, then rose by 18.11% to $4.2 million in 2024, then surged by 373.95% to $10.8 million in 2025.
  • Its last three reported values are $10.8 million in Q3 2025, $7.5 million for Q2 2025, and $6.2 million during Q1 2025.